

## Platelet Rich-Plasma

| Table of Content                              |  |
|---|--|
| <a href="#">Purpose</a>                       |  |
| <a href="#">Description &amp; Definitions</a> |  |
| <a href="#">Criteria</a>                      |  |
| <a href="#">Coding</a>                        |  |
| <a href="#">Document History</a>              |  |
| <a href="#">References</a>                    |  |
| <a href="#">Special Notes</a>                 |  |
| <a href="#">Keywords</a>                      |  |

|                                  |             |
|----------------------------------|-------------|
| <a href="#">Effective Date</a>   | 9/2007      |
| <a href="#">Next Review Date</a> | 1/2025      |
| <a href="#">Coverage Policy</a>  | Medical 246 |
| <a href="#">Version</a>          | 5           |

**Member-specific benefits take precedence over medical policy and benefits may vary across plans. Refer to the individual's benefit plan for details [\\*](#).**

### Purpose:

This policy addresses the medical necessity of platelet-rich plasma therapies.

### Description & Definitions:

Autologous platelet-rich plasma, a platelet concentrate suspended in plasma, is prepared from samples of centrifuged autologous blood. Platelets are stimulated to release a variety of growth factors by addition of thrombin and calcium. A platelet gel is created which has been used during surgery with the intent of accelerating healing and improving surgical outcomes. In addition, PRP has been studied for improving healing of chronic wounds. Platelet Rich-Plasma injection (including but not limited to bone marrow plasma injection and Autologous Platelet Rich-Plasma injections) is the administration of platelet-rich plasma into joint spaces, sites of pain or injury, augmentation, and fusion of bone to help heal and reduce pain.

### Criteria:

Platelet-rich plasma is medically necessary for the treatment of chronic non-healing diabetic wounds when clinical documentation supports that the individual meets **ALL** the following criteria:

- The individual's wound has failed to improve or has increased in size following at least a thirty-day trial of conservative wound care management. Clinical documentation, including size of wound and adherence to prescribed treatment must be included **All** the following:
  - Appropriate wound care management includes **Any** of the following:
    - Control of edema, venous hypertension, and/or lymphedema
    - Treatment of infection
    - Removal of any foreign body or malignancy
    - Debridement of necrotic tissue
    - Appropriate off-loading of pressure, protection from trauma, and elimination of aggravating factors
    - For venous stasis ulcers, compression therapy with diligent use of multilayer dressing of >20 mmHG pressure or pneumatic compression
  - The documentation must support that the wound **All** of the following:
    - does not involve tendon, muscle, joint capsule, exposed bone, or sinus tracts
    - has a clean granular base
    - is at least 1.0 cm in size

- is clean without necrotic debris or exudate
- has adequate circulation to support wound healing
- does not have evidence of infection or foreign body
- If applicable, the provider must have counseled the member on smoking cessation
- The documentation must support that the member's diabetes mellitus is under appropriate treatment
- For a duration of 20 weeks only

Platelet Rich Plasma is considered **not medically necessary** for uses other than those listed in the clinical criteria.

## Coding:

### Medically necessary with criteria:

| Coding | Description  |
|--------|--|
| 0232T  | Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed  |
| G0460  | Autologous platelet rich plasma (PRP) or other blood-derived product for nondiabetic chronic wounds/ulcers (includes, as applicable: administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment) |
| P9020  | Platelet rich plasma, each unit  |
| S0157  | Becaplermin gel 0.01%, 0.5 gm  |
| S9055  | Procuren or other growth factor preparation to promote wound healing   |

### Considered Not Medically Necessary:

| Coding | Description |
|--------|-------------|
|        | None        |

U.S. Food and Drug Administration (FDA) - approved only products only.

## Document History:

### Revised Dates:

- 2024: January
- 2023: July
- 2023: January
- 2022: January
- 2020: January
- 2015: March
- 2013: August
- 2012: August
- 2011: September
- 2010: December
- 2009: November

### Reviewed Dates:

- 2021: January
- 2018: October
- 2017: November
- 2016: August
- 2015: August
- 2014: August
- 2010: August, November

- 2009: August
- 2008: August

Effective Date:

- September 2007

## References:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

CFR - Code of Federal Regulations Title 21. TITLE 21--FOOD AND DRUGS. CHAPTER I--FOOD AND DRUG ADMINISTRATION. DEPARTMENT OF HEALTH AND HUMAN SERVICES. SUBCHAPTER F – BIOLOGICS. PART 640 -- ADDITIONAL STANDARDS FOR HUMAN BLOOD AND BLOOD PRODUCTS. Subpart D – Plasma. Sec. 640.34 Processing. Retrieved 1.8.2024.

<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcr/CFRSearch.cfm?fr=640.34#:~:text=Platelet%20rich%20plasma%20shall%20be,manipulation%20of%20the%20donor's%20tissue.>

[Code of Federal Regulations], [Title 21, Volume 7], [CITE: 21CFR640.32], TITLE 21--FOOD AND DRUGS, CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES, SUBCHAPTER F – BIOLOGICS, PART 640 -- ADDITIONAL STANDARDS FOR HUMAN BLOOD AND BLOOD PRODUCTS. Subpart D – Plasma, Sec. 640.32 Collection of source material.

<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcr/CFRSearch.cfm?fr=640.32>

Hayes, a symplr company. Platelet-Rich Plasma for Wound Treatment in Diabetic Foot Ulcers. April 2023. Retrieved 1.8.2024. <https://evidence.hayesinc.com/report/hta.ulcers5170>

Hayes, a symplr company. Platelet-Rich Plasma for Wound Treatment in Venous Leg Ulcers. December 202. Retrieved 1.8.2024. <https://evidence.hayesinc.com/report/dir.ulcers5171>

Centers for Medicare and Medicaid Services. CMS.gov. National Coverage Determination (NCD), Blood-Derived Products for Chronic Non-Healing Wounds, 270.3. Effective date 4.13.2021. Retrieved 1.8.2024.

<https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=217&ncdver=6>

Local Coverage Determination (LCD), Platelet Rich Plasma, L39071. Palmetto. Effective date 12.12.2021. Retrieved 1.8.2024. <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39071&ver=9>

Commonwealth of Virginia. MES Public Portal - Department of Medical Assistance Services. Provider Manuals. Retrieved 1.8.2024.

[https://vamedicaid.dmas.virginia.gov/pdf\\_chapter/practitioner#gsc.tab=0&gsc.q=platelet%20rich%20plasma&gsc.sort=](https://vamedicaid.dmas.virginia.gov/pdf_chapter/practitioner#gsc.tab=0&gsc.q=platelet%20rich%20plasma&gsc.sort=)

National Comprehensive Cancer Network. NCCN.org. Retrieved 1.8.2024. <https://www.nccn.org/search-result?indexCatalogue=nccn-search-index&searchQuery=platelet%20rich%20plasma>

Carelon Clinical Guidelines. Retrieved 1.8.2024. <https://www.carelon.com/search-results?q=platelet+rich+plasma>

American Association of Plastic Surgeons. 12.2020. The Evolving Role of Platelet-Rich Plasma (PPR) in Plastic Surgery. Retrieved 1.8.2024. <https://www.plasticsurgery.org/news/press-releases/the-evolving-role-of-platelet-rich-plasma-in-plastic-surgery>

PubMed. Kaushik, A., Kumaran, M. Platelet-Rich Plasma: The Journey so Far! Indian Dermatology Online. Sept 2020.

<https://pubmed.ncbi.nlm.nih.gov/33235832/#:~:text=PRP%20is%20rich%20in%20growth.any%20significant%20demonstrable%20adverse%20effects.>

PubMed. Gupta, S., Paliczak, A., Delgado, D. Evidence-based indications of platelet-rich plasma therapy. Expert Review of Hematology. 12.2020. Retrieved 1.8.2024. <https://pubmed.ncbi.nlm.nih.gov/33275468/>

### Special Notes: \*

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving, and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

Services mean both medical and behavioral health (mental health) services and supplies unless We specifically tell You otherwise. We do not cover any services that are not listed in the Covered Services section unless required to be covered under state or federal laws and regulations. We do not cover any services that are not Medically Necessary. We sometimes give examples of specific services that are not covered but that does not mean that other similar services are covered. Some services are covered only if We authorize them. When We say You or Your We mean You and any of Your family members covered under the Plan. Call Member Services if You have questions.

### Keywords:

SHP Bone Marrow Plasma Injection, SHP Medical 246, Prolotherapy, Medical 108, pain, healing, platelet rich plasma, PRP, platelet plasma